LONDON, Sept. 5, 2019 /PRNewswire/ -- Smith+Nephew (LSE:
SN, NYSE: SNN), the global medical technology business, today
announced the launch of its EVOS WRIST Plating System at the
American Society for Surgery of the Hand (ASSH) Annual Meeting in
Las Vegas, Nevada.
EVOS WRIST is an ultra-versatile plating system set that gives
surgeons a choice of approach, material, and locking technology to
perform simple and complex wrist fracture procedures exactly the
way they want to meet the specific needs of their patients.
"EVOS WRIST is a versatile, all-encompassing system with
options for volar, dorsal, and forearm plating," said Dr.
Louis W. Catalano of NYU Langone
Health and the Roosevelt Hand-Shoulder
Center-OrthoManhattan. "Different fractures have different
needs, and what sets the EVOS WRIST plating system apart is the
unique flexibility it provides me to choose the best option for my
patient."
EVOS WRIST offers both stainless steel and titanium volar plate
options, dorsal plates, and forearm specific plates. Stainless
volar plates utilize variable-angle locking technology to allow
more freedom in screw placement, as well as fixed-angle locking
technology in longer plates for extra-articular fractures. Titanium
options for fragment specific plates include distal ulna,
intermediate column, radial column, and dorsal buttress plates.
"We are excited about EVOS WRIST for what it offers our
customers – an expansive plating portfolio that's easy to use while
allowing for thoughtful consideration of all fracture types and
patterns for the wrist," said Craig
Gaffin, Vice President and General Manager for Trauma and
Extremities at Smith+Nephew. "It offers enhanced versatility on the
standard of care for wrist fractures and rounds out our diverse
portfolio of forearm/wrist/hand solutions – making it one of the
most comprehensive in the market."
EVOS WRIST is available in the US, Europe and several other global markets and
complements Smith+Nephew's comprehensive portfolio of plate and
screw systems including EVOS™ SMALL,
EVOS™ MINI and VLP
MINI-MOD™.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business that exists to restore people's bodies and
their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 16,000+
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Advanced
Wound Management and Sports Medicine & ENT. Founded in
Hull, UK, in 1856, we now operate
in more than 100 countries, and generated annual sales of
$4.9 billion in 2018. Smith+Nephew is
a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group'
and 'Smith+Nephew' are used to refer to Smith & Nephew
plc and its consolidated subsidiaries, unless the context
requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us
on Twitter, LinkedIn,
Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smithnephew-launches-new-evos-wrist-plating-system-an-evolutionary-treatment-option-for-both-simple-and-complex-wrist-fractures-300912278.html
SOURCE Smith & Nephew